Literature DB >> 16082525

[Avoiding emergency situations under anticoagulant therapy with vitamin K antagonists].

C E Dempfle1, M Borggrefe.   

Abstract

Despite 50 years of clinical experience with vitamin K antagonists such as phenprocoumon or warfarin, many clinicians are uncertain how to start treatment, deal with overdose or bleeding complications, and how to bridge anticoagulation when treatment with vitamin K antagonists is interrupted. Patients with overdose of vitamin K antagonists or bleeding complications are treated with vitamin K, prothrombin complex concentrates (PCC), or recombinant factor VIIa. Rapid reversal of anticoagulation is only achieved by using PCC or recombinant factor VIIa. Both should be combined with vitamin K for a sustained effect. For elective surgery, treatment with vitamin K antagonists is paused and vitamin K given either orally or intravenously. Unfractionated or low molecular weight heparin is given when INR levels are below therapeutic range. Patients with contraindications to heparin may be treated with alternative anticoagulants such as danaparoid, lepirudin or fondaparinux.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082525     DOI: 10.1007/s00108-005-1479-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  12 in total

1.  Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations.

Authors:  K Webster; J Wilde
Journal:  Br J Oral Maxillofac Surg       Date:  2000-04       Impact factor: 1.651

2.  Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation.

Authors:  John Fanikos; Kanella Tsilimingras; Nils Kucher; Allison B Rosen; Melissa D Hieblinger; Samuel Z Goldhaber
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

3.  A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization.

Authors:  Heyder Omran; Christoph Hammerstingl; Harald Schmidt; Giso von der Recke; Wilhelm Dieter Paar; Berndt Lüderitz
Journal:  Thromb Haemost       Date:  2003-08       Impact factor: 5.249

4.  Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients.

Authors:  F E Preston; S T Laidlaw; B Sampson; S Kitchen
Journal:  Br J Haematol       Date:  2002-03       Impact factor: 6.998

Review 5.  Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians.

Authors:  James D Douketis
Journal:  Thromb Res       Date:  2002-10-01       Impact factor: 3.944

6.  Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose.

Authors:  M Yasaka; M Oomura; K Ikeno; H Naritomi; K Minematsu
Journal:  Ann Hematol       Date:  2002-11-29       Impact factor: 3.673

Review 7.  Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Theodore E Warkentin; Andreas Greinacher
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

9.  Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.

Authors:  James D Douketis; Judith A Johnson; Alexander G Turpie
Journal:  Arch Intern Med       Date:  2004-06-28

Review 10.  Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy.

Authors:  Syed M Jafri
Journal:  Am Heart J       Date:  2004-01       Impact factor: 4.749

View more
  1 in total

1.  Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption.

Authors:  M Matsubara; E Yamachika; H Tsujigiwa; N Mizukawa; T Ueno; J Murakami; N Ishida; Y Kaneda; N Shirasu; S Takagi
Journal:  Osteoporos Int       Date:  2009-10-08       Impact factor: 4.507

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.